BR112021022789A2 - Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a - Google Patents

Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a

Info

Publication number
BR112021022789A2
BR112021022789A2 BR112021022789A BR112021022789A BR112021022789A2 BR 112021022789 A2 BR112021022789 A2 BR 112021022789A2 BR 112021022789 A BR112021022789 A BR 112021022789A BR 112021022789 A BR112021022789 A BR 112021022789A BR 112021022789 A2 BR112021022789 A2 BR 112021022789A2
Authority
BR
Brazil
Prior art keywords
tl1a
systems
methods
devices
selecting patients
Prior art date
Application number
BR112021022789A
Other languages
English (en)
Portuguese (pt)
Inventor
Dalin Li
P Mcgovern Dermot
Janine Bilsborough
Laurens Kruidenier
Mahyar Sabripour
Original Assignee
Cedars Sinai Medical Center
Prometheus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center, Prometheus Biosciences Inc filed Critical Cedars Sinai Medical Center
Publication of BR112021022789A2 publication Critical patent/BR112021022789A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112021022789A 2019-05-14 2020-05-13 Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a BR112021022789A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962847798P 2019-05-14 2019-05-14
PCT/US2020/032679 WO2020232125A1 (en) 2019-05-14 2020-05-13 Tl1a patient selection methods, systems, and devices

Publications (1)

Publication Number Publication Date
BR112021022789A2 true BR112021022789A2 (pt) 2022-04-19

Family

ID=73228513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022789A BR112021022789A2 (pt) 2019-05-14 2020-05-13 Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a

Country Status (12)

Country Link
US (5) US20200362025A1 (enExample)
EP (1) EP3969621A4 (enExample)
JP (2) JP2022533956A (enExample)
KR (1) KR20220088529A (enExample)
CN (1) CN114375339A (enExample)
AU (1) AU2020275413A1 (enExample)
BR (1) BR112021022789A2 (enExample)
CA (1) CA3140029A1 (enExample)
IL (1) IL288017A (enExample)
MX (1) MX2021013974A (enExample)
TW (1) TW202108614A (enExample)
WO (1) WO2020232125A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014007426B1 (pt) 2011-09-30 2023-01-03 Teva Pharmaceuticals Australia Pty Ltd Anticorpos contra tl1a e seus usos
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
MX2023005688A (es) * 2020-11-13 2023-07-18 Prometheus Biosciences Inc Metodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a.
WO2022140283A1 (en) * 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith
EP4294443A4 (en) * 2021-02-18 2025-08-20 Prometheus Biosciences Inc ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF PULMONARY TREATMENT
US20240209103A1 (en) * 2021-04-28 2024-06-27 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a
WO2024026395A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
EP4637819A1 (en) * 2022-12-22 2025-10-29 Prometheus Biosciences, Inc. Methods of treating inflammatory diseases with combination of tl1a inhibitors and s1pr inhibitors
WO2024173877A1 (en) * 2023-02-17 2024-08-22 Prometheus Biosciences, Inc. Anti-tl1a antibody compositions and methods of treatment in the liver
WO2024239006A1 (en) 2023-05-17 2024-11-21 Genentech, Inc. Anti-tl1a antibody therapeutic methods
WO2024249282A1 (en) * 2023-05-26 2024-12-05 Prometheus Biosciences, Inc. Methods, systems, and kits for treatment of inflammatory diseases by targeting tl1a
WO2025038473A1 (en) 2023-08-11 2025-02-20 Paragon Therapeutics, Inc. Tl1a binding antibodies and methods of use
US20250109209A1 (en) 2023-10-03 2025-04-03 Absci Corporation Tl1a associated antibody compositions and methods of use
WO2025240922A1 (en) 2024-05-17 2025-11-20 Genentech, Inc. Methods for treatment of inflammatory bowel disease with an anti-tl1a antibody
CN120089402A (zh) * 2025-03-10 2025-06-03 广州敏特生物技术有限公司 一种结合抗nf155抗体检测和酶联免疫吸附试验的检测方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
DE3684446D1 (de) 1985-12-28 1992-04-23 Sumitomo Pharma Arzneimittel mit verzoegerter stossweiser freisetzung.
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5523302A (en) 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US20030153063A1 (en) 2000-11-17 2003-08-14 Feder John N. Novel human G-protein coupled receptor, HGPRBMY11, expressed highly in heart and variants thereof
US20030224400A1 (en) 2000-11-17 2003-12-04 Barber Lauren E. Novel human G-protein coupled receptor, HGPRBMY11, and variants thereof
US7531310B2 (en) 2000-11-17 2009-05-12 Bristol-Myers Squibb Company Methods of diagnosing Crohn's disease by measuring expression level of RNA encoding human G-protein coupled receptor, HGPRBMY11
JP2004524023A (ja) 2000-12-29 2004-08-12 バイオ テクノロジー ジェネラル コーポレイション 選択的癌療法のための特異的ヒト抗体
SE0004928D0 (sv) 2000-12-29 2000-12-29 Apbiotech Ab A method for the manufacturing of porous material
MX337162B (es) 2001-01-05 2016-02-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
US10544459B2 (en) 2004-12-08 2020-01-28 Cedars-Sinai Medical Center Methods of using genetic variants for the diagnosis and treatment of inflammatory bowel disease
WO2006127900A2 (en) 2005-05-25 2006-11-30 Biogen Idec Ma Inc. Tl1a in the treatment of disease
JP5027209B2 (ja) 2006-04-07 2012-09-19 日立化成工業株式会社 クローン病患者の末梢血白血球におけるＴ細胞受容体介在性腫瘍壊死因子スーパーファミリー及びケモカインのｍＲＮＡ発現の増強
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100190162A1 (en) 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100136543A1 (en) 2007-03-02 2010-06-03 Universite De Liege Method for determining the genotype at the crohn's disease locus
US20150376707A1 (en) 2007-05-18 2015-12-31 Cedars-Sinai Medical Center Methods of diagnosing and treating inflammatory bowel disease
US9305137B1 (en) 2007-05-18 2016-04-05 Cedars-Sinai Medical Center Methods of identifying the genetic basis of a disease by a combinatorial genomics approach, biological pathway approach, and sequential approach
US20100240043A1 (en) 2007-10-19 2010-09-23 Cedars-Sinai Medical Center Methods of using genetic variants to diagnose and predict inflammatory bowel disease
CA2714713C (en) 2008-02-19 2018-02-27 The Children's Hospital Of Philadelphia Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
CA2734604A1 (en) 2008-08-25 2010-04-22 Centocor Ortho Biotech Inc. Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
EP2757160A3 (en) 2009-07-20 2014-07-30 Genentech, Inc. Gene expression markers for Crohn's disease
US8301232B2 (en) 2010-06-08 2012-10-30 Alivecor, Inc. Wireless, ultrasonic personal health monitoring system
CA2808417A1 (en) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Circulating biomarkers for disease
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
KR101934247B1 (ko) 2010-10-18 2019-01-02 네스텍 소시에테아노님 항-약물 항체 동종형의 확인 방법
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US9902996B2 (en) 2011-02-11 2018-02-27 Cedars-Sinai Medical Center Methods of predicting the need for surgery in crohn's disease
RU2013154566A (ru) 2011-05-10 2015-06-20 Нестек С.А. Способы анализа профиля активности болезни с целью проведения индивидуального лечения
EP2780467B1 (en) 2011-11-14 2018-10-17 Alfasigma S.p.A. Assays and methods for selecting a treatment regimen for a subject with depression and methods for treatment
KR20150117259A (ko) 2013-01-02 2015-10-19 그렌마크 파머수티칼스 에스. 아. Tl1a에 결합하는 항체 및 이의 용도
AU2014241162A1 (en) 2013-03-27 2015-10-22 Cedars-Sinai Medical Center Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways
EP2997165A4 (en) 2013-05-17 2017-03-08 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
RU2015155552A (ru) 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
EP4105236A1 (en) 2013-07-19 2022-12-21 Cedars-Sinai Medical Center Anti-tl1a (tnfsf15) antibody for treatment of inflammatory bowel disease
US10349888B2 (en) 2013-10-08 2019-07-16 Carlos Federico Muniz Wearable electroencephalography device and methods of use thereof
US9683998B2 (en) * 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
WO2022187196A1 (en) 2021-03-02 2022-09-09 Dermtech, Inc. Predicting therapeutic response
WO2015136446A1 (en) 2014-03-11 2015-09-17 Nestec S.A. Methods for selecting antidepressant drug therapy to treat depression
CN106102767B (zh) 2014-03-27 2021-08-10 豪夫迈·罗氏有限公司 用于诊断和治疗炎症性肠病的方法
US10261098B2 (en) 2014-08-18 2019-04-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biomarkers for diagnosis and management of neuro-immunological diseases
WO2016040879A1 (en) 2014-09-12 2016-03-17 The Board Of Trustees Of The Leland Stanford Junior University Physical examination method and apparatus
CA2964857A1 (en) 2014-10-20 2016-04-28 Nestec S.A. Methods for prediction of anti-tnf alpha drug levels and autoantibody formation
WO2016134306A1 (en) 2015-02-20 2016-08-25 Mc10, Inc. Automated detection and configuration of wearable devices based on on-body status, location, and/or orientation
US10407725B2 (en) 2015-08-21 2019-09-10 The Children's Hospital Of Philadelphia Methods of treating autoimmune conditions in patients with genetic variations in DcR3 or in a DcR3 network gene
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US10732092B2 (en) 2015-12-22 2020-08-04 University Of Maryland, College Park Analysis of single cell mechanical phenotyping for metastatic detection
CN109462996A (zh) 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2017189846A1 (en) 2016-04-27 2017-11-02 Thaddeus Stappenbeck Methods for prognosing crohn's disease comprising human defensin 5 (hd5)
US10458996B1 (en) 2016-05-20 2019-10-29 Beth Israel Deaconess Medical Center, Inc. Methods for determining clinical response to TNF-alpha and/or JAK inhibitors in subjects with inflammatory diseases
CN109476698B (zh) 2016-05-20 2023-10-17 西达-赛奈医疗中心 基于基因的炎性肠病诊断
KR20240128132A (ko) 2016-10-26 2024-08-23 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
EP3562523A4 (en) 2016-12-29 2020-09-30 Tempo Therapeutics, Inc. PROCESSES AND SYSTEMS FOR THE TREATMENT OF A MEDICAL IMPLANT SITE
US20190070166A1 (en) 2017-09-02 2019-03-07 Richard Postrel Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
US10961581B2 (en) 2017-03-22 2021-03-30 Board Of Regents, The University Of Texas System Method to identify subjects at higher risk to develop an autoimmune disease based on genetic and/or phenotypic screening for epistatic variants in DDX39B (RS2523506) and IL7R (RS6897932)
US10635787B2 (en) 2017-04-19 2020-04-28 International Business Machines Corporation Analysis of output files
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
US12105089B2 (en) 2017-07-17 2024-10-01 The Broad Institute, Inc. Cell atlas of the healthy and ulcerative colitis human colon
US20220112625A1 (en) 2017-09-02 2022-04-14 Richard Postrel Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses
EP3695229A1 (en) 2017-10-10 2020-08-19 Prometheus Biosciences, Inc. Methods for monitoring vedolizumab treatment
WO2019079647A2 (en) 2017-10-18 2019-04-25 Wuxi Nextcode Genomics Usa, Inc. IA STATISTICS FOR DEEP LEARNING AND PROBABILISTIC PROGRAMMING, ADVANCED, IN BIOSCIENCES
WO2019178005A2 (en) 2018-03-12 2019-09-19 Sqz Biotechnologies Company Methods for treating hpv-associated diseases
WO2019186691A1 (ja) 2018-03-27 2019-10-03 日産自動車株式会社 自動運転車両の制御方法および制御装置
TW202012635A (zh) 2018-04-24 2020-04-01 美國錫安山醫學中心 用於表徵重度克隆氏症(crohn's disease)之方法及系統
KR20250024101A (ko) 2018-04-25 2025-02-18 프로메테우스 바이오사이언시즈, 인크. 최적화된 항tl1a 항체
WO2019210203A1 (en) 2018-04-27 2019-10-31 Cedars-Sinai Medical Center Compositions and methods of targeting gpr35 for the treatment of inflammatory bowel conditions
KR20250111409A (ko) 2018-04-30 2025-07-22 세다르스-신나이 메디칼 센터 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템
CA3105464A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
US20220260565A1 (en) 2018-10-15 2022-08-18 Cedars-Sinai Medical Center Methods of treating and diagnosing inflammatory bowel disease
WO2020082090A1 (en) 2018-10-19 2020-04-23 The Regents Of The University Of Michigan Method for monitoring autoimmune disease
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
CA3121167A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020139748A1 (en) 2018-12-28 2020-07-02 Cedars-Sinai Medical Center Methods of treating inflammatory bowel diseases that target ripk2
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
BR112021015222A2 (pt) 2019-02-08 2021-12-28 Cedars Sinai Medical Center Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
CA3128942A1 (en) 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
SG11202109333SA (en) 2019-02-28 2021-09-29 Sqz Biotechnologies Co Delivery of biomolecules to pbmcs to modify an immune response
KR20220088529A (ko) 2019-05-14 2022-06-27 프로메테우스 바이오사이언시즈, 인크. Tl1a 환자 선택 방법, 시스템 및 장치
WO2020242976A1 (en) 2019-05-24 2020-12-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of polygenic diseases and phenotypes from genetic variation
WO2021016090A1 (en) 2019-07-19 2021-01-28 The Regents Of The University Of Michigan Compositions and methods for individualized characterization of non-ige mediated food allergies
TWI871367B (zh) 2019-10-24 2025-02-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a(tl1a)之人類化抗體及其用途
IL292419A (en) 2019-10-24 2022-06-01 Prometheus Biosciences Inc Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
EP4065727A4 (en) 2019-11-27 2024-03-27 Cedars-Sinai Medical Center PREDICTING EXTRAINTESTINAL MANIFESTATIONS OF INFLAMMATORY BOWEL DISEASE
WO2021247770A1 (en) 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
CA3180628A1 (en) 2020-06-03 2021-12-09 Rebecca GONSKY Treatments for a sub-population of inflammatory bowel disease patients
CA3187966A1 (en) 2020-06-26 2021-12-30 Pfizer Inc. Methods of treating inflammatory bowel disease with tl1a antibodies
WO2022087313A1 (en) 2020-10-22 2022-04-28 Progenity, Inc. Methods of treating and predicting non-response to anti-tnf treatment in subjects with gastrointestinal tract diseases
WO2022091085A1 (en) 2020-10-26 2022-05-05 Technion Research & Development Foundation Limited Methods of assessing the therapeutic activity of agents for the treatment of immune disorders
MX2023005688A (es) 2020-11-13 2023-07-18 Prometheus Biosciences Inc Metodos, sistemas y equipos para el tratamiento de enfermedades inflamatorias dirigidas al tl1a.
CA3200256A1 (en) 2020-12-01 2022-06-09 Rebecca GONSKY Methods and systems of stratifying inflammatory disease patients
WO2022140283A1 (en) 2020-12-21 2022-06-30 Cedars-Sinai Medical Center Tl1a therapy compositions and methods of treatment therewith
EP4294443A4 (en) 2021-02-18 2025-08-20 Prometheus Biosciences Inc ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF PULMONARY TREATMENT
EP4294444A4 (en) 2021-02-18 2025-04-16 Prometheus Biosciences, Inc. Compositions containing humanized antibodies against TNF-like ligand 1A (TL1A) and uses thereof
EP4305425A2 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Methods for predicting treatment response in ulcerative colitis
US20240209103A1 (en) 2021-04-28 2024-06-27 Cedars-Sinai Medical Center Patient selection methods and kits for therapies targeting tl1a

Also Published As

Publication number Publication date
TW202108614A (zh) 2021-03-01
US20200362025A1 (en) 2020-11-19
US12215147B2 (en) 2025-02-04
JP2022533956A (ja) 2022-07-27
JP2025092795A (ja) 2025-06-20
KR20220088529A (ko) 2022-06-27
US20230018729A1 (en) 2023-01-19
EP3969621A1 (en) 2022-03-23
CN114375339A (zh) 2022-04-19
WO2020232125A1 (en) 2020-11-19
US20210101988A1 (en) 2021-04-08
CA3140029A1 (en) 2020-11-19
IL288017A (en) 2022-01-01
US12391752B2 (en) 2025-08-19
US11136386B2 (en) 2021-10-05
US20230272061A1 (en) 2023-08-31
AU2020275413A1 (en) 2021-12-23
EP3969621A4 (en) 2023-01-25
MX2021013974A (es) 2022-02-10
US20250340627A1 (en) 2025-11-06

Similar Documents

Publication Publication Date Title
BR112021022789A2 (pt) Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
BR112018068906A2 (pt) composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
ECSP18081954A (es) Detección de infección microbiana en heridas
BR112018072560A2 (pt) terapia de combinação para tratamento do câncer
MX2020002150A (es) Terapia de combinación para el tratamiento del cáncer.
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
MX387283B (es) Tratamiento del cancer con tg02.
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BR112015024300A2 (pt) sistema de planejamento de terapia para tratamento de um alvo interno de um paciente, método de aplicação de terapia para tratamento de um alvo interno de um paciente, um ou mais processadores programados para controlar o tratamento de uma parte interna de um paciente, mídia legível por computador não temporária, e sistema de aplicação de terapia para tratamento de um alvo interno de um paciente
BR112015023439A2 (pt) combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki
BR112016008694A2 (pt) Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
MX337081B (es) Anticuerpo anti-nr10 y su uso.
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
CR20110128A (es) Metodos, sistemas y productos para predecir la respuesta de las celulas tumorales a un agente terapeutico y tratar a un paciente de acuerdo con la respuesta predicha
MX388914B (es) Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer.
BR112023009172A2 (pt) Métodos, sistemas e kits para tratamento de doenças inflamatórias direcionados à tl1a
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
BR112014020233A2 (pt) seleção de paciente com câncer para administração de inibidores sinalizantes wnt usando status de mutação rnf43
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
BR112019003533A2 (pt) terapia de combinação com inibidores de glutaminase
BR112017023170A2 (pt) dispositivo de banho medicinal e seu uso
BR112018074152A2 (pt) métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
BR112019009495A2 (pt) métodos de tratamento de distúrbios inflamatórios com compostos de fc multivalentes